All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
On 14 November 2018, the National Institute for Health and Care Excellence (NICE) published an appraisal guidance recommending gemtuzumab ozogamicin (Mylotarg®), with daunorubicin and cytarabine, as an option for untreated de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia, in people 15 years and over.1
This recommendation would only be applicable if patients start induction therapy when either the cytogenetic test confirms that the disease has favorable, intermediate or unknown cytogenetics (that is because the test was unsuccessful) or when their cytogenetic test results are not yet available and they start consolidation therapy. In addition, the recommendation by NICE is also dependent on the drug manufacturers, providing gemtuzumab ozogamicin according to the commercial arrangement.1
Gemtuzumab ozogamicin, an antibody-drug conjugate (ADC), is an antibody-targeted chemotherapeutic agent consisting of a humanized murine CD33 antibody. Since it is a humanized anti-CD33 monoclonal antibody, it is highly specific for targeting leukemic blasts. As a result, this ADC can then dispense the anti-tumor antibiotic calicheamicin to CD33-expressing tumor cells.2
In April 2018, the European Commission (EC) granted approval to gemtuzumab ozogamicin in combination with daunorubicin and cytarabine for the treatment of patients aged 15 years and above with previously untreated, de novo, CD33-positive AML. The approval by the EC for Mylotarg was based on results obtained from the phase III ALFA-701 study (NCT00927498). Data from the ALFA-701 study showed that combination of Mylotarg with standard chemotherapy regimen in newly diagnosed de novo AML patients significantly improved 3-year event-free survival and relapse-free survival (RFS) compared to chemotherapy alone.3
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox